HY Zhang, George K. K. Lau, Scott Bowden, Nikolai V. Naoumov, F. Rousseau, Nikki P. Lee, Anita Wong, Nancy Leung, Chee-Kin Hui, Stephen Locarnini, Sharon R Lewin, Herve Mommeja-Marin, and John M. Luk
Volume 44, no. 8, p. 2983-2987, 2006. Pages 2983 to 2987: “Molecular Beacons assay” should read “in-house assay” throughout. Page 2983, column 2. Lines 1 to 5 should read as follows. “… A prototype assay was also developed by Abbott Laboratories (Abbott Park, IL), but the product was never commercialized (1). One commercial assay that has been developed is the RealART HBV LC PCR kit (Artus GmbH, Hamburg, Germany). An in-house real-time PCR assay has also been developed (10a, 17a). In this study, we evaluated the performance characteristics of the RealART HBV LC PCR kit and the in-house assay and compared them…” Page 2984, column 1. Lines 40 to 56 should read as follows. “Molecular beacon analysis. HBV viral loads were determined using real-time PCR as previously described (10a). The primers and molecular beacon probe sequences were selected from conserved regions within the precore domain of the HBV genome. Standard curves were generated using 10-fold serial dilutions (1.3 × 107 to 1.3 × 101) of a pBlueBac plasmid ligated with a supergenomic length of HBV DNA. Real-time PCR was performed in 50 μl total volume containing 0.5× TaqMan buffer A (Applied Biosystems), 0.5× TaqMan Buffer II, 3.0 mM MgCl2, 1.25 U AmpliTaq Gold, 0.4 pmol/ml of HBV-specific beacon TW5 (CGC[GTCCTACTGTTCAAGCCTCCAAGCTGTG]A[C]GCG), 0.4 pmol/ml of forward primer PC1 (5′-GGGAGGAGATTAGGTTAA-3′), 0.4 pmol/ml of reverse primer PC2 (5′-GGCAAAAACGAGAGTAACTC-3′) and 5 μl of either patient DNA or plasmid standard. PCR conditions were 95°C for 10 min followed by 45 cycles of 94°C for 15 s, 50°C for 30 s, and 72°C for 30 s.” Page 2984, column 2, line 6: “(1)” should read “(1a).” Page 2986, column 1, line 32: “(1)” should read “(1a).” Page 2986: Reference 1 should be reference 1a. Page 2986: The following reference was inadvertently omitted. Page 2987: The following references were inadvertently omitted. 1. Abravaya, K., J. Huff, R. Marshall, B. Merchant, C. Mullen, G. Schneider, and J. Robinson. 2003. Molecular beacons as diagnostic tools: technology and applications. Clin. Chem. Lab. Med. 41:468-474. 10a. Lewin, S. R., R. M. Ribeiro, T. Walters, G. K. Lau, S. Bowden, S. Locarnini, and A. S. Perelson. 2001. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34:1012-1020. 17a. Wightman, F., T. Walters, A. Ayres, S. Bowden, A. Bartholomeusz, D. Lau, S. Locarnini, and S. R. Lewin. 2004. Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of lamivudine-resistant hepatitis B virus strains. J. Clin. Microbiol. 42:3809-3812.